-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Neurodegenerative diseases can cause the weakness of nerve cells to continue to degenerate or die, as well as a series of problems in thinking, attention and memory
Currently, there are approximately 850,000 dementia patients in the UK, which is expected to increase to 1.
prevention
The biomarkers currently used to identify neurodegenerative diseases are extracted from lumbar puncture cerebrospinal fluid (CSF)
A core and irreversible feature of many neurodegenerative diseases is damage to nerve fibers, which leads to the release of a protein called neurofilament light chain (NfL) in the blood
diagnosis
Recently, a new study of more than 3,000 people conducted by a team of King’s College London (KCL) and Lund University (Lund) showed for the first time that NfL levels can accurately indicate that people with cognitive problems have potential neurodegeneration.
NfL levels can accurately indicate the presence of underlying neurodegeneration in people with cognitive problems, such as Down’s syndrome dementia, motor neuron disease (ALS), and frontotemporal dementia
The study examined 3138 samples, including people without cognitive impairment, people with neurodegenerative diseases, people with Down syndrome, and people with depression
Compared with people without cognitive problems, all patients with neurodegenerative diseases have higher levels of NfL in the blood.
Plasma neurofilament (NfL) in different diagnostic groups of KCL and Lund .
Plasma neurofilament (NfL) in different diagnostic groups of KCL and Lund .
Although blood-based NfL cannot distinguish all diseases, it can provide insight into different groups in certain diseases
In the sample from King’s College London, these age-related cut-off points are 90% accurate in highlighting neurodegeneration in people over 65, and 100% accurate in detecting motor neuron diseases and Down’s syndrome dementia Sex, there are very similar results in Lund’s sample
NfL can distinguish patients with depression from patients with neurodegenerative diseases, the latter usually manifested as primary mental disorders in the early stages of disease development, such as frontotemporal dementia
The performance of plasma neurofilament (NfL) in identifying neurodegenerative diseases, the control group (CU and SCD)> 65 years old (A), the control group (CU and SCD) <65 years old (B) and depression (C)
The performance of plasma neurofilament (NfL) in identifying neurodegenerative diseases, the control group (CU and SCD)> 65 years old (A), the control group (CU and SCD) <65 years old (B) and depression (C)This study shows that in adults with Down syndrome who are genetically predisposed to Alzheimer's disease, neurofilament chain levels are particularly high
In adults with Down syndrome who are genetically predisposed to Alzheimer's disease, the level of neurofilament chain is particularly high
This new marker may be used to improve the diagnosis of Alzheimer's disease in patients with Down syndrome and as a biomarker to show whether the treatment is effective
NfL is a promising biomarker that can speed up the diagnosis of neurodegenerative diseases and shorten clinical trials.
NfL is a promising biomarker that can speed up the diagnosis of neurodegenerative diseases and shorten clinical trials.
Co-senior author of the study, from King's College London and South London and Maudsley NHS Foundation Abdul Dr.
Hye NIHR Biomedical Research Center of the Maudsley Trust, said: "We show for the first time in a number of diseases, a Biomarkers can very accurately indicate the existence of underlying neurodegeneration
.
Although it is not specific for any kind of disease, it can help services such as memory clinics as a quick screening tool to identify memory, thinking or mental problems Whether it is the result of neurodegeneration
.
At the same time, Dr.
Hye also pointed out that blood-based NfL provides a scalable and widely used alternative to invasive and expensive tests for dementia
.
In some European countries, such as Sweden or the Netherlands, it has been used as a routine assessment, and our age-related demarcation line can provide clinicians with a benchmark and quick test to indicate those who exhibit problems with thinking and memory Human neurodegeneration
.
Co-senior author, Professor Oskar Hansson of Lund University, said: "Blood testing has great potential in improving the diagnosis of dementia in specialized memory clinics and primary care
.
Plasma NfL is very useful in many clinical situations and can be useful for doctors.
Provide a lot of information, as this large-scale research shows'
.
Lead author Dr.
Nicholas Ashton of King’s College London concluded: "We are entering an exciting period of blood tests like plasma NfL combined with other emerging blood biomarkers such as phosphorylated tau (p-tau).
, Is beginning to give us a meaningful and non-invasive insight into brain diseases
.
Original source:
A multicentre validation study of the diagnostic value of plasma neurofilament light.
DOI: 10.
1038/s41467-021-23620-z
1038/s41467-021-23620-z
Leave a message here